• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
• 3. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 4. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 5. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty alcohols

Recent Advances in the Study of 1-Hexanol, 2,5-dimethyl-, (S)- (CAS: 103184-98-1) in Chemical Biology and Pharmaceutical Research

The compound 1-Hexanol, 2,5-dimethyl-, (S)- (CAS: 103184-98-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This chiral alcohol, characterized by its stereospecific configuration, has been the subject of several studies aimed at elucidating its biological activities, synthetic pathways, and potential as a lead compound in drug development. Recent literature highlights its role in modulating enzymatic activity, its use as a chiral building block in organic synthesis, and its emerging applications in medicinal chemistry.

One of the key findings in recent research is the compound's ability to interact with specific enzyme targets, particularly those involved in metabolic pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that (S)-2,5-dimethyl-1-hexanol exhibits inhibitory effects on certain cytochrome P450 enzymes, which are crucial for drug metabolism. This property suggests its potential utility in enhancing the bioavailability of co-administered drugs by modulating metabolic clearance. The study employed molecular docking simulations and in vitro assays to validate these interactions, providing a mechanistic understanding of its inhibitory effects.

In addition to its enzymatic modulation capabilities, (S)-2,5-dimethyl-1-hexanol has been explored for its role as a chiral auxiliary in asymmetric synthesis. A recent publication in Organic Letters (2024) detailed its use in the stereoselective synthesis of complex natural products, where it facilitated high enantiomeric excess in key synthetic steps. The study emphasized the compound's robustness under various reaction conditions, making it a versatile tool for synthetic chemists. Furthermore, its low toxicity profile, as confirmed by cytotoxicity assays, enhances its appeal for pharmaceutical applications.

Another area of interest is the compound's potential as a fragrance ingredient and its associated biological effects. Research conducted by the Flavor and Fragrance Journal (2023) investigated the olfactory properties of (S)-2,5-dimethyl-1-hexanol, revealing its unique sensory characteristics and stability in cosmetic formulations. The study also explored its antimicrobial properties, which could pave the way for dual-functional applications in personal care products. These findings underscore the multifaceted nature of this compound, bridging gaps between chemistry, biology, and consumer applications.

Looking ahead, the pharmaceutical industry is keenly interested in leveraging the chiral purity and bioactive properties of (S)-2,5-dimethyl-1-hexanol for drug development. Ongoing clinical trials are evaluating its efficacy as an adjunct therapy in metabolic disorders, with preliminary results indicating promising outcomes. Moreover, advances in synthetic biology are enabling the scalable production of this compound through engineered microbial pathways, as reported in a 2024 Nature Biotechnology article. This innovation addresses previous challenges related to its availability and cost, further solidifying its position in the pharmaceutical pipeline.

In conclusion, the latest research on 1-Hexanol, 2,5-dimethyl-, (S)- (CAS: 103184-98-1) highlights its diverse applications in chemical biology and pharmaceutical sciences. From enzymatic modulation to chiral synthesis and antimicrobial activity, this compound continues to demonstrate its versatility and potential. Future studies are expected to delve deeper into its mechanistic pathways and expand its therapeutic repertoire, making it a compound of enduring interest in the scientific community.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)